FDA approval granted for immune response modifier for precancerous skin lesions.

Publication: Immunotherapy Weekly

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2004 NewsRX

2004 MAR 31 - (NewsRx.com & NewsRx.net) -- According to the American Academy of Dermatology, actinic keratosis (AK) affects as many as 10 million Americans each year.

Caused by chronic sun exposure, actinic keratoses are precancerous skin lesions, many of which can occur on the face and scalp.

3M announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Aldara (imiquimod) cream, 5%, a topical prescription treatment for clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on...

Read the full article for free courtesy of your local library.